Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jacob Laubach, M.D.

Co-Author

This page shows the publications co-authored by Jacob Laubach and Nikhil Munshi.
Connection Strength

1.698
  1. Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1209-16.
    View in: PubMed
    Score: 0.124
  2. Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):947-60.
    View in: PubMed
    Score: 0.108
  3. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia. 2009 Dec; 23(12):2222-32.
    View in: PubMed
    Score: 0.107
  4. Bortezomib in the management of multiple myeloma. Cancer Manag Res. 2009 Sep 08; 1:107-17.
    View in: PubMed
    Score: 0.107
  5. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021 03; 22(3):e105-e118.
    View in: PubMed
    Score: 0.059
  6. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996.
    View in: PubMed
    Score: 0.057
  7. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020 07 20; 38(21):2380-2389.
    View in: PubMed
    Score: 0.056
  8. Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Am J Hematol. 2019 11; 94(11):1244-1253.
    View in: PubMed
    Score: 0.054
  9. The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease. Clin Adv Hematol Oncol. 2018 Aug; 16(8):564-574.
    View in: PubMed
    Score: 0.050
  10. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018 07; 182(2):222-230.
    View in: PubMed
    Score: 0.049
  11. Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia. 2018 08; 32(8):1838-1841.
    View in: PubMed
    Score: 0.048
  12. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015 Jun; 169(6):843-50.
    View in: PubMed
    Score: 0.040
  13. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res. 2015 Oct 15; 21(20):4607-18.
    View in: PubMed
    Score: 0.040
  14. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015 Jun; 169(6):851-8.
    View in: PubMed
    Score: 0.039
  15. Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? Hematology Am Soc Hematol Educ Program. 2014 Dec 05; 2014(1):255-61.
    View in: PubMed
    Score: 0.038
  16. Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. Clin Cancer Res. 2014 Aug 01; 20(15):3955-61.
    View in: PubMed
    Score: 0.037
  17. Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol. 2014 Aug; 166(3):401-9.
    View in: PubMed
    Score: 0.037
  18. Phase transitions in human IgG solutions. J Chem Phys. 2013 Sep 28; 139(12):121904.
    View in: PubMed
    Score: 0.036
  19. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013 Jul 01; 19(13):3640-8.
    View in: PubMed
    Score: 0.035
  20. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013 Apr 11; 121(15):2975-87.
    View in: PubMed
    Score: 0.034
  21. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013 Mar 14; 121(11):1961-7.
    View in: PubMed
    Score: 0.034
  22. Pathological crystallization of human immunoglobulins. Proc Natl Acad Sci U S A. 2012 Aug 14; 109(33):13359-61.
    View in: PubMed
    Score: 0.033
  23. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur J Haematol. 2012 May; 88(5):446-9.
    View in: PubMed
    Score: 0.032
  24. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012 Feb 21; 9(3):135-43.
    View in: PubMed
    Score: 0.032
  25. Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol. 2012 Feb; 5(1):51-66; quiz 67-8.
    View in: PubMed
    Score: 0.032
  26. Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. Blood. 2012 Apr 12; 119(15):e131-8.
    View in: PubMed
    Score: 0.032
  27. The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol. 2012 Jan; 88(1):1-7.
    View in: PubMed
    Score: 0.031
  28. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol. 2011 Nov 10; 29(32):4243-9.
    View in: PubMed
    Score: 0.031
  29. Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol. 2011 Sep; 154(6):755-62.
    View in: PubMed
    Score: 0.030
  30. MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. Oncology (Williston Park). 2011 Jun; 25(7):594, 596.
    View in: PubMed
    Score: 0.030
  31. A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol. 2011 Jul; 86(7):573-8.
    View in: PubMed
    Score: 0.030
  32. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol. 2011 Mar; 12(3):263-72.
    View in: PubMed
    Score: 0.030
  33. Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol. 2011 Feb; 152(4):420-32.
    View in: PubMed
    Score: 0.029
  34. Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. 2010 Jun 15; 4:215-45.
    View in: PubMed
    Score: 0.028
  35. The treatment of multiple myeloma patients not eligible for asct. Mediterr J Hematol Infect Dis. 2010 May 03; 2(2):e2010009.
    View in: PubMed
    Score: 0.028
  36. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park). 2010 Mar; 24(3 Suppl 2):22-9.
    View in: PubMed
    Score: 0.028
  37. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4.
    View in: PubMed
    Score: 0.028
  38. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol. 2009 Apr; 46(2):166-75.
    View in: PubMed
    Score: 0.026
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.